Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

Biochemical and Biophysical Research Communications

Volumn 299, Issue 1, 2002, Pages 25-28

  Yasar, Umit ^a   Lundgren, Stefan ^a   Eliasson, Erik ^a   Bennet, Anna ^b   Wiman, Björn ^a   De Faire, Ulf ^b   Rane, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C8; CYP2C9; Genetic linkage; Polymorphism

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; ISOENZYME; NUCLEASE;

ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; METABOLISM; METABOLITE; PHYSIOLOGY; PRIORITY JOURNAL;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, GENETIC;

OVIS ARIES;

EID: 0036433338     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02592-5     Document Type: Article

References (17)

1. J.A. Goldstein, Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br. J. Clin. Pharmacol. 52 (2001) 349-355.
2. K. Takanashi, H. Tainaka, K. Kobayashi, T. Yasumori, M. Hosakawa, K. Chiba, CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates, Pharmacogenetics 10 (2000) 95-104.
3. U. Yasar, G. Tybring, M. Hidestrand, M. Oscarson, M. Ingelman-Sundberg, M.L. Dahl, E. Eliasson, Role of CYP2C9 polymorphism in losartan oxidation, Drug Metab. Dispos. 29 (2001) 1051-1056.
4. J.O. Miners, D.J. Birkett, Cytochrome P4502C9: An enzyme of major importance in human drug metabolism, Br. J. Clin. Pharmacol. 45 (1998) 525-538.
5. J. Kirchheiner, J. Brockmoller, I. Meineke, S. Bauer, W. Rohde, C. Meisel, I. Roots, Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers, Clin. Pharmacol. Ther. 71 (2002) 286-296.
6. G.P. Aithal, C.P. Day, P.J. Kesteven, A.K. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet 353 (1999) 717-719.
7. D. Dai, D.C. Zeldin, J.A. Blaisdell, B. Chanas, S.J. Coulter, B.I. Ghanayem, J.A. Goldstein, Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid, Pharmacogenetics 11 (2001) 597-607.
8. K. Leander, J. Hallqvist, C. Reuterwall, A. Ahlbom, U. de Faire, Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: Results from the Stockholm Heart Epidemiology Program (SHEEP), Epidemiology 12 (2001) 215-221.
9. C. Reuterwall, J. Hallqvist, A. Ahlbom, U. De Faire, F. Diderichsen, C. Hogstedt, G. Pershagen, T. Theorell, B. Wiman, A. Wolk, Higher relative, but lower absolute risks of myocardial infarction in women than in men: Analysis of some major risk factors in the SHEEP study, The SHEEP Study Group, J. Intern. Med. 246 (1999) 161-174.
10. K.J. Livak, Allelic discrimination using fluorogenic probes and the 5′ nuclease assay, Genet. Anal. 14 (1999) 143-149.
11. U. Yasar, E. Eliasson, M.L. Dahl, I. Johansson, M. Ingelman-Sundberg, F. Sjoqvist, Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population [published erratum appears in Biochem. Biophys. Res. Commun. 1999 Apr;258:227], Biochem. Biophys. Res. Commun. 254 (1999) 628-631.
12. U. Yasar, E. Aklillu, R. Canaparo, M. Sandberg, J. Sayi, H.-K. Roh, A. Wennerholm, Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations, Eur. J. Clin. Pharmacol. (2002), in press.
13. R.S. Kidd, T.B. Curry, S. Gallagher, T. Edeki, J. Blaisdell, J.A. Goldstein, Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin, Pharmacogenetics 11 (2001) 803-808.
14. A. Gaedigk, W.L. Casley, R.F. Tyndale, E.M. Sellers, M. Jurima-Romet, J.S. Leeder, Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations, Can. J. Physiol. Pharmacol. 79 (2001) 841-847.
15. K. Inoue, H. Yamazaki, T. Shimada, Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian, Xenobiotica 28 (1998) 403-411.
16. K. Mamiya, I. Ieiri, S. Miyahara, J. Imai, H. Furuumi, Y. Fukumaki, H. Ninomiya, N. Tashiro, H. Yamada, S. Higuchi, Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients, Pharmacogenetics 8 (1998) 87-90.
17. I. Fleming, U.R. Michaelis, D. Bredenkotter, B. Fisslthaler, F. Dehghani, R.P. Brandes, R. Busse, Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries, Circ. Res. 88 (2001) 44-51.